LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

38.13 1.54

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

38.13

Max

38.13

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.4M -81M
EPS	-0.5
Angestellte	205
EBITDA	-6.8M -79M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+39.74% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.4B 5.6B
Vorheriger Eröffnungskurs	36.59
Vorheriger Schlusskurs	38.13

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Feb. 2026, 17:37 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

20. Feb. 2026, 16:18 UTC

Wichtige Markttreiber

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

20. Feb. 2026, 23:12 UTC

Akquisitionen, Fusionen, Übernahmen

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20. Feb. 2026, 22:12 UTC

Ergebnisse

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. Feb. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. Feb. 2026, 21:23 UTC

Ergebnisse

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20. Feb. 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20. Feb. 2026, 21:01 UTC

Akquisitionen, Fusionen, Übernahmen

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20. Feb. 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

20. Feb. 2026, 20:17 UTC

Market Talk

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

20. Feb. 2026, 20:11 UTC

Market Talk

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

20. Feb. 2026, 19:59 UTC

Market Talk

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

20. Feb. 2026, 19:58 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

20. Feb. 2026, 19:49 UTC

Market Talk

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

20. Feb. 2026, 19:09 UTC

Market Talk

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

20. Feb. 2026, 19:00 UTC

Market Talk

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

20. Feb. 2026, 18:28 UTC

Market Talk

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

20. Feb. 2026, 18:20 UTC

Market Talk

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

20. Feb. 2026, 18:05 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

20. Feb. 2026, 18:04 UTC

Market Talk

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

20. Feb. 2026, 17:38 UTC

Market Talk

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

20. Feb. 2026, 17:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Feb. 2026, 17:24 UTC

Market Talk

Correction to Treasury Yields Fall Market Talk

20. Feb. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

20. Feb. 2026, 16:53 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

20. Feb. 2026, 16:53 UTC

Market Talk

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

20. Feb. 2026, 16:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Feb. 2026, 16:45 UTC

Market Talk

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

20. Feb. 2026, 16:40 UTC

Market Talk

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

39.74% Vorteil

12-Monats-Prognose

Durchschnitt 52.18 USD 39.74%

Hoch 67 USD

Tief 35 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.